7 results
Drug Induced Lupus vs SLE
Drug Induced Lupus (DIL):
 • Epidemiology: -10% of all lupus cases, drug-dependent,
NPSLE rare, Malar rash ... Discontinuation of causal ... Lupusreference #druginduced ... #table #rheumatology ... #diagnosis #management
Systemic Lupus Erythematosus (SLE) - Diagnosis and Management Summary
 • Epidemiology: 10-180/100,000, Typically Age 20-40, F:M
Systemic Lupus Erythematosus ... Manifestations: Malar rash ... Positive in 60-80% of cases ... life-threatening • Treatment ... #Summary #rheumatology
CNS Manifestations of Systemic Lupus Erythematosus (SLE)

Clinical Manifestations: Demyelinating Syndrome, Headache, Movement disorders, Seizure disorders, Aseptic
Demyelinating Syndrome ... autoantibodies that will cause ... CNS #neurology #rheumatology ... cerebritis #diagnosis #management ... #treatment
Behcet's Syndrome - Treatment
Ulcers:
 • Treatment: Topical steroids
 • Prevention: Colchicine
 • Azathioprine for refractory disease
Arthritis:
Behcet's Syndrome ... : • Treatment: ... Behcets #disease #Syndrome ... #Treatment #management ... #pharmacology #rheumatology
Kawasaki Disease (KD) - Diagnosis and Management Summary

Kawasaki Disease (KD) is the most common vasculitis of
, Cough • +/-Nausea ... Polymorphous rash ... KD #vasculitis #rheumatology ... #pediatrics #diagnossi ... #management #treatment
Macrophage Activation Syndrome (MAS)
Classified among the secondary or acquired forms of haemophagocytic lymphohistiocytosis (sHLH)

What?
A subset of
Petechial or purpuric rash ... SJIA], systemic lupus ... Treatment: • Corticosteroids ... #Diagnosis #Management ... #Hematology #Rheumatology
Drug Induced Lupus (DIL)
 • Epidemiology: -10% of all lupus cases, drug-dependent, 4:1 to 1:1 F:M
NPSLE rare, Malar rash ... Discontinuation of causal ... Lupusreference #DrugInduced ... #Lupus #DIL #rheumatology ... #management